Good morning fellow allies.
We’re thrilled to report a new treatment for metastatic breast cancer has just been negotiated at pCPA, bringing it one step closer to the women who need it. For women living with MBC, swift access to treatments means more time and the potential to live a better life longer.
That’s why last fall we called on the Rethink community to be allies for women living with MBC. Amazingly, nearly 2,000 of you answered with your pledge.
This isn’t the first time our community has shown how passionate and dedicated they are about this cause. We’ve come a long way and have done a lot of hard work together. That deserves some recognition. Here’s a reminder of where we’ve been and what we’ve accomplished.
1October 2017: 10,000 Rethinkers Make A Commitment To Women Living With MBC
10,000 rethinkers signed the #MBCinthedark petition, committing to making our health system better for everyone by bring the voices and values of women with metastatic breast cancer into the light.
2October 19, 2017: Rethink Heads To Queen’s Park
With the strength of our petition signers, Rethink and over 40 advocates represented the MBC community in Queen’s Park to bring greater visibility to the reality of unknowns that those with metastatic breast cancer currently face.
3September 2018:The pCPA Announces New Benchmarks
4October 2018: You Answer Our Call For Allies
We call for 1,000 allies to help keep governing bodies and drug manufacturers accountable to these newly announced benchmarks. Nearly 2,000 of you answer the call.
5October 25, 2018: Rethink Heads Back To Queen’s Park
Rethink headed to Queen’s Park with more than 40 advocates to show decision makers that we are watching, and ready to move if benchmarks and promises weren’t kept.
6November 2018 – April 2019: Rethink Keeps Pressure On pCPA And Drug Manufacturer
The Rethink team works behind the scenes to keep the pressure on the pCPA and the manufacturer through meetings and calls with key stakeholders. Although we play a role as a trusted partner, having nearly 2,000 allies who are counting on them to uphold their commitments, helps strengthen our voice.
7May 2019: Progress Is Made For New Breast Cancer Drug Kisqali (Ribociclib)
Proof your voice can make a difference. The manufacturer and pCPA have negotiated a drug price and signed a letter of intent for Kisqali (ribociclib). This was done in half the time it took to for the last breast cancer drug to be negotiated.